Article
Multidisciplinary Sciences
Karolina Pavic, Nikhil Gupta, Judit Domenech Omella, Rita Derua, Anna Aakula, Riikka Huhtaniemi, Juha A. Maatta, Nico Hofflin, Juha Okkeri, Zhizhi Wang, Otto Kauko, Roosa Varjus, Henrik Honkanen, Daniel Abankwa, Maja Kohn, Vesa P. Hytonen, Wenqing Xu, Jakob Nilsson, Rebecca Page, Veerle Janssens, Alexander Leitner, Jukka Westermarck
Summary: This study reveals the molecular level details and structural mechanisms of PP2A-B56 alpha inhibition by the oncoprotein CIP2A. CIP2A displaces the PP2A-A subunit and forms a pseudotrimer, blocking the B56 alpha substrate binding site and stabilizing CIP2A protein.
NATURE COMMUNICATIONS
(2023)
Review
Genetics & Heredity
Beibei Chen, Huihui Hu, Xiaobing Chen
Summary: Cancerous inhibitor of protein phosphatase 2A (CIP2A), also known as p90, is highly expressed in various tumors and interacts with protein phosphatase 2A (PP2A) and c-Myc. This interaction hinders PP2A from inducing c-Myc S62 and stabilizes c-Myc protein. CIP2A/p90 plays a crucial role in tumorigenesis, including cell proliferation, invasion, migration, and drug resistance, and has potential as a therapeutic target. Furthermore, autoantibodies against CIP2A/p90 in sera may serve as biomarkers for certain types of cancer diagnosis. This review focuses on recent advances and future research implications of CIP2A/p90.
FRONTIERS IN GENETICS
(2023)
Article
Neurosciences
Sijia Yin, Chao Han, Yun Xia, Fang Wan, Junjie Hu, Liang Kou, Yadi Sun, Jiawei Wu, Yunna Li, Qiulu Zhou, Nian Xiong, Jinsha Huang, Tao Wang
Summary: This study identified and validated cancerous inhibitor of PP2A (CIP2A) as a potential diagnostic biomarker for Parkinson's disease (PD). The results showed that plasma CIP2A concentrations were significantly lower in PD patients compared to controls, and CIP2A played a role in PD-related pathogenesis in cellular and mouse models. This suggests that CIP2A could be a novel biomarker for PD.
MOLECULAR NEUROBIOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Qinglin Zhang, Jiadong Pan, Fangmei An, He Nie, Qiang Zhan
Summary: This study found that decreased expression of SLC39A1 is associated with clinical features and survival rates in early-stage hepatocellular carcinoma (EHCC), with patients showing lower expression having poorer prognosis. The expression level of SLC39A1 may serve as a potential diagnostic and prognostic biomarker for EHCC patients.
Article
Gastroenterology & Hepatology
Marina Serra, Mario Di Matteo, Jens Serneels, Rajesh Pal, Sarah Trusso Cafarello, Martina Lanza, Carlos Sanchez-Martin, Matthias Evert, Alessandra Castegna, Diego Francesco Calvisi, Massimiliano Mazzone, Amedeo Columbano
Summary: The study shows that Ldha deletion significantly impairs mouse HCC development, suggesting lactate dehydrogenase as a potential target to enhance the efficacy of current therapeutic options.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Cell Biology
Baozhu Zhang, Qing Zhou, Qiankun Xie, Xiaohui Lin, Wenqiang Miao, Zhaoguang Wei, Tingting Zheng, Zuoliang Pang, Haosheng Liu, Xi Chen
Summary: This study characterized the differential expression of SPC25 in HCC patients of different races and HBV infection status. The findings suggest that increased expression of SPC25 is associated with poor prognosis of HCC and enhances the proliferative capacity of HCC cells. SPC25 could serve as a valuable prognostic marker and a novel treatment target for HCC.
Article
Pathology
Lucy M. Han, Kar Wan Lee, Gunay Uludag, Michael I. Seider, Armin R. Afshar, Michele M. Bloomer, Melike Pekmezci
Summary: In this study, we demonstrated that UM could be successfully risk-stratified using a combination of BAP1 and PRAME immunohistochemical stains. The increase in study risk group based on loss of BAP1 expression and positive PRAME staining was associated with higher rates of metastasis and disease-specific death, as well as lower metastasis-free survival and disease-specific survival.
Article
Pharmacology & Pharmacy
Lin Che, Jia-Shen Wu, Chi-Yu Xu, Yu-Xin Cai, Jin-Xian Lin, Ze-Bang Du, Jia-Zhang Shi, Tun Han, Yu-Qiao He, Yu-Chun Lin, Zhong-Ning Lin
Summary: This study investigates the role of phosphorylated dynamin-related protein 1 (p-Drp1(Ser616)) in regulating mitochondria-lysosome crosstalk and mediating anti-hepatocellular carcinoma (HCC) therapy. The results demonstrate that p-Drp1(Ser616) interacts with Rab7 to trigger increased mitochondria-lysosome crosstalk and promote PINK1-Parkin-dependent mitophagy and anti-apoptosis in HCC cells. The study also shows that B56 gamma-mediated dephosphorylation of p-Drp1Ser616 inhibits mitophagy and increases mitochondria-dependent apoptosis.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Oncology
Dan-Dan Zhang, Wen-Er Wang, Yu-Shui Ma, Yi Shi, Jie Yin, Ji-Bin Liu, Xiao-Li Yang, Rui Xin, Da Fu, Wen Jie Zhang
Summary: The study identified the miR-212-3p/SLC6A1 axis as a potential crucial therapeutic target for HCC. Analysis of gene expression and protein levels confirmed the down-regulated expression of SLC6A1 in HCC tissues, as well as the negative correlation between SLC6A1 expression and DNA methylation.
CANCER MANAGEMENT AND RESEARCH
(2021)
Review
Oncology
Fabio Giannone, Nevena Slovic, Patrick Pessaux, Catherine Schuster, Thomas F. Baumert, Joachim Lupberger
Summary: Hepatocellular carcinoma is a deadly cancer that is often detected late with limited treatment options. The lack of reliable prognostic biomarkers hinders the prediction of HCC recurrence. Inflammatory markers offer potential tools for improving prognosis and decision-making in liver surgeons and hepatologists.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Dafeng Xu, Yu Wang, Jincai Wu, Shixun Lin, Yonghai Chen, Jinfang Zheng
Summary: A four-gene signature construct based on EMT-associated genes was developed to study the pathogenesis and clinical management of HCC. The construct showed robust and reliable predictive efficacy, validated across different datasets from various platforms.
CANCER CELL INTERNATIONAL
(2021)
Article
Biochemistry & Molecular Biology
Juan Kong, Di Li, Shidong Zhang, Huixia Zhang, Yuanyuan Fu, Bo Qian, Chunhua Bei, Shengkui Tan, Xiaonian Zhu
Summary: Okadaic acid (OA) has been found to promote the epithelial-mesenchymal transition (EMT) process of hepatocellular carcinoma cells, enhancing their invasion and migration abilities while decreasing the activity of protein phosphatase 2A (PP2A). This indicates that OA plays a role in promoting metastasis of HCC.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2021)
Review
Oncology
Aroosha Raja, Farhan Haq
Summary: This review extensively summarizes current information on molecular classification of HCC, providing insight for understanding the development mechanisms and treatment options for liver cancer patients globally.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Cell Biology
Wen Zhang, Zhongjian Liu, Shilin Xia, Lei Yao, Lan Li, Ziying Gan, Hui Tang, Qiang Guo, Xinmin Yan, Zhiwei Sun
Summary: The elevated expression of GDI2 in HCC patients is associated with more aggressive tumor status, including severe primary tumor extent, advanced pathological stage, and mutated TP53 status. High GDI2 expression is strongly correlated with a poor survival rate. Enrichment and immune infiltration analyses suggest that GDI2-associated signaling involves lipid metabolism and ECM constructing pathways related to the tumor microenvironment.
Article
Biochemistry & Molecular Biology
Hongbin Zhang, Ke Xu, Qin Xiang, Lijuan Zhao, Benxu Tan, Ping Ju, Xiufu Lan, Yi Liu, Jian Zhang, Zheng Fu, Chao Li, Jinzhi Wang, Jixiang Song, Yun Xiao, Zhaobo Cheng, Yan Wang, Shu Zhang, Tingxiu Xiang
Summary: This study revealed that LPCAT1 was significantly overexpressed in HCC tumor tissues and correlated with various clinicopathologic parameters. LPCAT1 expression independently predicted the overall survival of patients with HCC and may be involved in the development of HCC through cell cycle regulation.